KURA Kura Oncology Inc
Company Analysis
Latest News
🔴 Kura Oncology is trading 5.6% down in pre-market as the reason for the drop remains unclear
Kura Oncology is trading $9.42, down 5.61% in pre-market; the reason for the decline remains unclear. - Its investor-relations press-release page lists...
🟢 Kura Oncology is trading 5% up today amid broader biotech-sector strength
Kura Oncology is trading at $9.83, up 5.07%, amid broader biotech-sector strength; no company-specific catalyst has been identified. - No clear October 20...
🔴 Kura Oncology is trading 5% down amid tech-led market sell-off
Kura Oncology is trading at $9.18, down 5.36%, amid broader risk-off selling; no clear company-specific catalyst explains the October 16 decline. - Kura had...
🔴 Kura Oncology is trading 5% down
Kura Oncology is trading 5.05% lower at $9.87; no clear company-specific news was found to explain the decline. - The October 13 announcement concerns a...
🟢 Kura Oncology is trading 5% up in pre-market
Kura Oncology is trading at $11.20, up +5.16%, in pre-market; no clearly confirmed October 5 catalyst directly explaining the move was found. - UBS reiterated...
🔴 Kura Oncology is trading 6.3% down in pre-market — reason remains unclear
Kura Oncology is trading 6.3% lower at $10.12 before the September 30, 2026 open; the reason for the decline remains unclear. - Supplied price context lists...
🔴 Kura Oncology is trading 5% down today as oil prices and Treasury yields pressure equities
Kura Oncology is trading 5.16% lower at $11.12, with the decline appearing primarily tied to weaker overall market sentiment. - Major U.S. indexes are falling...
🟢 Kura Oncology is trading 5.49% up today amid broader biotech rally
Kura Oncology is trading 5.49% up now at $11.81, moving alongside a broader biotech rally rather than a newly reported company-specific catalyst. - Biotech’s...
🔴 Kura Oncology is trading 5.25% down today after hotter-than-expected producer inflation
Kura Oncology is trading 5.25% down at $11.46 amid broad market weakness following hotter-than-expected producer inflation and renewed concerns about delayed...
Kura Oncology Forms Subsidiary Caspian Therapeutics with $50M Series A Financing
Kura Oncology has formed a new subsidiary, Caspian Therapeutics, Inc., to focus on developing next-generation menin inhibitors for diabetes and other...
Kura Oncology launches Caspian with $50M, targeting diabetes reversal
Kura Oncology launched Caspian Therapeutics to advance a pipeline of small-molecule menin inhibitors. Caspian secured $50 million in a financing round led by...
🔴 Kura Oncology is trading 5.22% down today amid broader market weakness
Kura Oncology is trading 5.22% down at $12.56 amid broader market weakness, with no confirmed company-specific catalyst. - The company announced Jennifer Fulk...
Kura Oncology Appoints Jennifer Fulk as New Chief Financial Officer
Kura Oncology announced the appointment of Jennifer Fulk as the company's new Chief Financial Officer, principal financial officer, and principal accounting...
Kura Oncology Earns Zacks Upgrade, Driven by KOMZIFTI Commercial Rollout
Zacks Investment Research upgraded Kura Oncology, Inc. to a Rank #2 (Buy) on September 2, 2026. Rising earnings estimates prompted the positive shift in...
Connor Clark & Lunn Buys $11M Kura Oncology Stake, Citing KOMZIFTI Sales
Connor Clark & Lunn Investment Management Ltd. opened a new position in Kura Oncology, Inc. during the second quarter. The firm purchased 996,114 shares. This...
🟢 Kura Oncology is trading 10.4% up today after CEO purchased $1.24 million in shares
Kura Oncology is trading at $13.69, up +10.40%, after President and CEO Troy Wilson purchased 100,000 shares for approximately $1.24 million on August 24,...
🟢 Kura Oncology is trading 8.47% up today after CEO bought 100,000 shares
Kura Oncology is trading 8.47% up now at $13.45 after President and CEO Troy Wilson purchased 100,000 shares for approximately $1.24 million on August 24,...
Kura Oncology's CEO Keeps Buying Stock With His Own Money — Is He Seeing Something Wall Street Hasn't Priced In?
Shares of Kura Oncology surged 11.3% to $13.80 after a regulatory filing revealed President and CEO Troy Wilson scooped up another 100,000 shares for roughly...
🟢 Kura Oncology is trading 11.29% up in pre-market after CEO discloses another 100,000-share purchase
Kura Oncology is trading 11.29% up in pre-market at $13.80 after President and CEO Troy Wilson disclosed another purchase of 100,000 shares on August 24,...
🟢 Kura Oncology is trading 6.1% up in pre-market after CEO buys another 100,000 shares
Kura Oncology is trading 6.13% up now at $13.16 after President and CEO Troy Wilson disclosed a second 100,000-share purchase. - The August 24, 2026 purchase...